Ho, Victor <br/><br/>
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.  [electronic resource] 

 -  Oncotarget  Sep 2015 
 - 27252-66 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.4583  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis<br/>CD8-Positive T-Lymphocytes--cytology<br/>Carboxymethylcellulose Sodium--analogs & derivatives<br/>Carcinoma, Hepatocellular--pathology<br/>Cell Line, Tumor<br/>Cell Proliferation<br/>Cell Survival<br/>Disease Progression<br/>Extracellular Signal-Regulated MAP Kinases--metabolism<br/>Humans<br/>Immune System<br/>Immunosuppressive Agents--chemistry<br/>Liver Neoplasms--pathology<br/>MAP Kinase Kinase Kinases--metabolism<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Inbred NOD<br/>Mice, SCID<br/>Niacinamide--administration & dosage<br/>Phenylurea Compounds--administration & dosage<br/>Phosphorylation<br/>Poly I-C--chemistry<br/>Polylysine--analogs & derivatives<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Signal Transduction<br/>Sorafenib<br/>Toll-Like Receptor 3--agonists